Amit Bhalodia, DO
Family Medicine · Camden, NJNPI 1982692083
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,507 of the $5,897 with a category attached, or 76.4%. 31 manufacturers reported payments, led by Boehringer Ingelheim at 25.1% of the total. 2025 is the largest year on record at $1,925, 2.4 times the $793 reported in 2019. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- AstraZeneca$655
- Sanofi-aventis U.S. LLC$635
- AbbVie$479
- Lilly USA, LLC$367
- Bayer$347
- plus $2K from 25 others
Across 220 payments — averaging $3184.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$606K
- Vertex$39K
- Boehringer Ingelheim International GmbH$31K
- Pfizer$25K
What the payments were for
- Speaking & faculty fees$3005%
- Travel & lodging$1,09018%
- Food & beverage$4,50776%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 18 | $1,480 |
| AstraZeneca | 31 | $655 |
| Sanofi-aventis U.S. LLC | 27 | $635 |
| AbbVie(2 entities) | 21 | $479 |
| Lilly USA, LLC | 26 | $367 |
| Bayer | 10 | $347 |
| Pfizer | 14 | $218 |
| GSK | 17 | $209 |
| Merck | 15 | $196 |
| Phathom Pharmaceuticals, Inc. | 6 | $175 |
| Exact Sciences | 8 | $171 |
| Biohaven Pharmaceuticals, Inc. | 1 | $164 |
| Novo Nordisk | 8 | $163 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $139 |
| Abbott | 4 | $83 |
| Novartis | 4 | $60 |
| Alkermes, Inc. | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $41 |
| Astellas Pharma US Inc | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Amgen | 2 | $27 |
| Qiagen, LLC | 2 | $24 |
| Verona Pharma, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Strongbridge US Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$300
- Kerendia$234
- UBRELVY$220
- NURTEC ODT$164
- BREZTRI$125
- VOQUEZNA$125
- QULIPTA$120
How this compares
$5,897 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 110 | $99,643 |
| JanuviaSitagliptin Phosphate | 104 | $99,572 |
| OzempicSemaglutide | 58 | $59,996 |
| FarxigaDapagliflozin Propanediol | 69 | $44,213 |
| EliquisApixaban | 49 | $39,168 |
| TrulicityDulaglutide | 25 | $33,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,105 |
| LinzessLinaclotide | 36 | $24,013 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $22,509 |
| TradjentaLinagliptin | 25 | $19,125 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $17,539 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $16,040 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $14,602 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 20 | $7,977 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Belsomra | $196 | $126,828147 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,480 | $118,768135 claims |
| Novo NordiskOzempic | $163 | $59,99658 claims |
| AstraZenecaFarxiga, Symbicort | $655 | $48,13686 claims |
| PfizerEliquis, Prempro, Premarin | $218 | $45,63178 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $209 | $40,14677 claims |
| Lilly USA, LLCTrulicity | $367 | $33,40225 claims |
| AbbVieLinzess | $479 | $24,01336 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $635 | $17,53921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Camden
- Christopher ColopintoCamden$20K
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.